Lycazid-M Tablet is a combination oral hypoglycemic agent containing Gliclazide 80 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea derivative, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels, while Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity. This dual mechanism provides effective glycemic control in patients inadequately managed by diet and exercise alone. Lycazid-M is particularly beneficial for patients with insulin resistance and those who require enhanced glycemic regulation without the risk of significant weight gain. The tablet should be administered orally, usually once or twice daily with meals to minimize gastrointestinal side effects commonly associated with Metformin, such as nausea, diarrhea, and abdominal discomfort. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy to ensure safety and efficacy. Contraindications include severe renal impairment, metabolic acidosis, and known hypersensitivity to either component. Caution is advised in patients with cardiovascular disease or hepatic dysfunction. Lycazid-M Tablet offers a synergistic approach to glycemic management, improving patient compliance and metabolic outcomes in type 2 diabetes mellitus.